StockNews.com initiated coverage on shares of Minerva Neurosciences (NASDAQ:NERV – Free Report) in a research note issued to investors on Sunday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.
Separately, HC Wainwright decreased their target price on shares of Minerva Neurosciences from $7.00 to $5.00 and set a neutral rating on the stock in a research report on Wednesday, August 7th.
Read Our Latest Analysis on NERV
Minerva Neurosciences Stock Performance
Minerva Neurosciences (NASDAQ:NERV – Get Free Report) last released its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($1.09) earnings per share for the quarter, missing the consensus estimate of ($0.97) by ($0.12). Sell-side analysts predict that Minerva Neurosciences will post -2.26 EPS for the current fiscal year.
Minerva Neurosciences Company Profile
Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.
Featured Articles
- Five stocks we like better than Minerva Neurosciences
- How to Start Investing in Real Estate
- Symbotic’s Double-Bagger Potential as It Hits a Key Inflection
- What is a Stock Market Index and How Do You Use Them?
- High Dividend Yields Make These 2 Shipping Stocks Stand Out
- The 3 Best Fintech Stocks to Buy Now
- Can Celsius Stock Rebound? Analysts See 74% Upside Potential
Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.